Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Public ClinicalTrials.gov record NCT05935748. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Study identification
- NCT ID
- NCT05935748
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Enrollment
- 18 participants
Conditions and interventions
Conditions
- Adenocarcinoma
- Advanced Renal Cell Carcinoma
- Carcinoma
- Carcinoma, Renal Cell
- Clear Cell Renal Cell Carcinoma
- Kidney Cancer
- Kidney Diseases
- Kidney Neoplasms
- Metastatic Renal Cell Carcinoma
- Neoplasm by Histology
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Recurrent Renal Cell Carcinoma
- Refractory Renal Cell Carcinoma
- Renal Cancer
- Renal Neoplasms
- Urogenital Neoplasms
- Urologic Diseases
- Urologic Neoplasms
- ccRCC
Interventions
- NKT2152 Drug
- palbociclib Drug
- sasanlimab Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 27, 2023
- Primary completion
- Jun 29, 2025
- Completion
- Sep 3, 2025
- Last update posted
- Nov 11, 2025
2023 – 2025
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego | La Jolla | California | 92093 | — |
| Northwestern University - Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan-Rogel Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065-6094 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390-9324 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05935748, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 11, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05935748 live on ClinicalTrials.gov.